APOE and amyloidosis: Furthermore, knock-in of the human APOE4 variant exacerbates tau pathology and neurodegeneration as compared to APOE2 and APOE3. In humans, APOE4 carriers display a higher level of neurodegeneration for a similar level of amyloid pathology [11, 63] and seem to progress faster to more advanced stages of the disease [67].